Headquartered in Northridge, CA Fiscal year ends April NASDAQ: MMED minimed.com
MiniMed Group Inc. is a global diabetes technology company that designs, manufactures, and sells insulin delivery systems, continuous glucose monitors (CGMs), algorithms, and connected app experiences. The company's integrated ecosystem includes insulin pumps (such as MiniMed 780G, MiniMed Flex, MiniMed Go, and the upcoming MiniMed Fit patch pump), CGM sensors (including Simplera and third-party sensors like Abbott's Instinct), consumable supplies, smart insulin pens, and advanced automated insulin delivery algorithms (including the Vivera fully-closed loop system in development). MiniMed serves people with diabetes in more than 80 countries, with a business mix weighted toward international markets. The company has been in the insulin delivery business for over 40 years and trades on Nasdaq under the ticker MMED. Updated
Medtronic just extended a nearly half-century dividend streak, but its raise barely outpaces inflation while rivals like Abbott and J&J grow payouts far faster. Whether explosive growth in cardiac ablation can close…
Pre-Market Stock Futures: The futures are trading lower on Tuesday, but another week and another set of new highs for the S&P 500 and the Nasdaq, as AI fever overshadowed Iran’s peace…
Pre-Market Stock Futures: Futures are trading higher this morning after reports are circulating that President Trump wants to end the war soon. This comes after Monday’s session, which saw three of the…
MiniMed Group Inc. is a global diabetes technology company that designs, manufactures, and sells insulin delivery systems, continuous glucose monitors (CGMs), algorithms, and connected app experiences.
24/7 Wall St.'s 12-month price target for MMED is $30.84, rated Buy. The Wall Street consensus target is $25.47. MMED price prediction →
